cysteine drug

cysteine drug
0 rating(s) (0 ø)

For conventional ADC production, 8 nucleophilic cysteine residues are first liberated from the reduced inter-chain disulfide bonds via reducing agents and they are later conjugated with drug-linker complexes. This approach generates ADCs with heterogeneous conjugation sites and a different number of drugs attached, resulting in a drug to antibody ratio (DAR) ranging from 0~8. As an example, Adcetris, one of the FDA approved ADCs, is prepared via non-specific cysteine drug conjugation.

All rights reserved

• This video may not be used, copied nor changed without explicit consent of the author.
 - Uploaded at 09.11.2017
The maximum length of a comment is 1000 characters.
The maximum length of an alias is 30 characters.
Please enter a comment.
Please insert a valid comment!